STOCK TITAN

Aspira Women’s Health (AWHL) OKs stock plan share increase and auditor

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Aspira Women’s Health Inc. reported the results of its 2026 annual stockholder meeting. Of 43,500,411 common shares entitled to vote as of the record date, 27,144,522 shares were represented, a quorum of 62.40%.

Stockholders elected all six director nominees for one‑year terms and approved, on an advisory basis, the compensation of the company’s named executive officers. They also approved an amendment to the 2019 Stock Incentive Plan to add 5,000,000 shares, bringing the total shares authorized under the plan to 9,532,818.

In addition, stockholders ratified the selection of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2026.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Shares entitled to vote 43,500,411 shares Common stock issued, outstanding and entitled to vote on record date
Shares represented at meeting 27,144,522 shares Shares present in person or by proxy (62.40% quorum)
Quorum percentage 62.40% Portion of entitled shares present at 2026 annual meeting
Plan share increase 5,000,000 shares Additional shares authorized under 2019 Stock Incentive Plan
Total plan authorization 9,532,818 shares Total shares authorized under 2019 Stock Incentive Plan after amendment
Auditor ratification for votes 22,810,174 votes Votes cast for ratifying BDO USA, P.C. for year ending Dec. 31, 2026
broker non-votes financial
"ABSTENTIONS | | | BROKER NON-VOTES |"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
advisory basis financial
"stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers"
2019 Stock Incentive Plan financial
"approved an amendment to the Company’s 2019 Stock Incentive Plan (the “2019 Plan”)"
independent registered public accounting firm financial
"ratified the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Aspira Women’s Health (AWHL) stockholders vote on at the 2026 annual meeting?

Stockholders voted on electing six directors, approving executive compensation on an advisory basis, amending the 2019 Stock Incentive Plan, and ratifying BDO USA, P.C. as the independent registered public accounting firm for 2026.

How many Aspira Women’s Health (AWHL) shares were eligible and represented at the meeting?

A total of 43,500,411 common shares were issued, outstanding, and entitled to vote, with 27,144,522 shares present in person or by proxy, representing 62.40% of eligible shares and establishing a valid quorum.

Was the Aspira Women’s Health (AWHL) 2019 Stock Incentive Plan amendment approved?

Yes, stockholders approved increasing the shares authorized under the 2019 Stock Incentive Plan by 5,000,000, so that a total of 9,532,818 shares of common stock are authorized to be granted under the plan going forward.

Did Aspira Women’s Health (AWHL) stockholders approve executive compensation?

Yes, in a non-binding advisory vote, stockholders approved the compensation of the company’s named executive officers as described in the April 20, 2026 definitive proxy statement filed with the Securities and Exchange Commission.

Which audit firm did Aspira Women’s Health (AWHL) stockholders ratify for 2026?

Stockholders ratified the selection of BDO USA, P.C. as Aspira Women’s Health Inc.’s independent registered public accounting firm for the year ending December 31, 2026, confirming the firm’s role in auditing that fiscal year’s financial statements.

Were all Aspira Women’s Health (AWHL) director nominees elected?

Yes, all six director nominees, including Ellen Beausang and Jane Pine Wood, were elected to one-year terms expiring at the next annual meeting, each receiving more votes cast for than against their election.
Aspira Women's Health Inc.0000926617false00009266172026-01-302026-01-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  June 17, 2026

ASPIRA WOMEN’S HEALTH INC.

(Exact name of registrant as specified in its charter)

Delaware

  ​ ​ ​

001-34810

  ​ ​ ​

33-0595156

(State or other jurisdiction of

(Commission

(IRS Employer

incorporation or organization)

File Number)

Identification No.)

12117 Bee Caves RoadBuilding IIISuite 100

AustinTX 78738

(Address of principal executive office) (Zip Code)

(512519-0400

(Registrants’ telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  ​ ​ ​

Trading Symbol(s)

  ​ ​ ​

Name of each exchange on which registered

Common Stock, par value $0.001

AWHL

OTC QX Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 17, 2026, Aspira Women’s Health Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). As of the close of business on the record date for the Annual Meeting, there were 43,500,411 shares of the Company’s common stock, par value $0.001 per share, issued and outstanding and entitled to vote. There were 27,144,522 shares present in person or by proxy at the Annual Meeting, or 62.40%, constituting a quorum. The final voting results were as follows:

 

Proposal 1: Election of Directors

 

The Company’s stockholders elected each of the Company’s six nominees for director for a one-year term expiring at the Company’s 2026 annual meeting of stockholders and until their successors are elected and qualified, as set forth below:

 

NOMINEE

 

FOR

 

 

AGAINST

 

 

ABSTENTIONS

 

 

BROKER NON-VOTES

 

Ellen Beausang

 

 

5,989,004

 

 

 

327,224

 

 

 

34,689

 

 

 

16,569,699

 

Jeffrey Cohen, M.D.

 

 

5,990,548

 

 

 

325,667

 

 

 

34,702

 

 

 

16,569,699

 

John Fraser

 

 

6,278,119

 

 

 

38,109

 

 

 

34,689

 

 

 

16,569,699

 

Cynthia Hundorfean

 

 

5,991,040

 

 

 

325,188

 

 

 

34,689

 

 

 

16,569,699

 

Winfred Parnell, M.D.

 

 

5,989,187

 

 

 

327,040

 

 

 

34,690

 

 

 

16,569,699

 

Jane Pine Wood

5,983,931

332,046

34,940

16,569,699

 

Proposal 2: Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers

 

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 20, 2026, as set forth below:

 

FOR

 

 

AGAINST

 

 

ABSTENTIONS

 

 

BROKER NON-VOTES

 

 

5,568,783

 

 

 

505,829

 

 

 

276,305

 

 

 

16,569,699

 

 

Proposal 3: Approval of an Amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan

 

The Company’s stockholders approved an amendment to the Company’s 2019 Stock Incentive Plan (the “2019 Plan”) to increase the number of shares of common stock authorized to be granted under the 2019 Plan by 5,000,000 shares so that a total of 9,532,818 shares of common stock are authorized to be granted under the 2019 Plan, as set forth below:

 

FOR

 

 

AGAINST

 

 

ABSTENTIONS

 

 

BROKER NON-VOTES

 

 

5,654,497

 

 

 

624,233

 

 

 

72,187

 

 

 

16,569,699

 

 

Proposal 4: Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm

 

The Company’s stockholders ratified the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026, as set forth below:

 

FOR

 

 

AGAINST

 

 

ABSTENTIONS

 

 

BROKER NON-VOTES

 

 

22,810,174

 

 

 

15,244

 

 

 

95,198

 

 

 

0

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: June 17, 2026

 

ASPIRA WOMEN’S HEALTH INC.

 

 

 

 

By:

/s/ John Strahley

 

Name: 

John Strahley

 

Title:

Chief Financial Officer

Filing Exhibits & Attachments

3 documents